Proteus S.A.
http://proteus-bio.cl/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Proteus S.A.
First ‘Digital Medicine’ Approved, Slow Rollout Planned
FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.
Astellas, Chromocell In Pain Pact Worth $515m-plus
Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.
Start-Up News April 2007
An emerging market in stroke rehabiliatation, and advancing the diagnosis and treatment of ophthalmic diseases.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- PROTEUS-BIO
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice